We also propose that both IgM+ and switched memory B cells may provide a good indication of vaccine efficacy, and that individuals with large numbers of IgM+ memory B cells may be better protected from future re-infection with homotypic or heterotypic infection. This evidence concerns the gene CD40LG and infection.